Weekly Analysts’ Ratings Changes for Syros Pharmaceuticals (SYRS)

A number of firms have modified their ratings and price targets on shares of Syros Pharmaceuticals (NASDAQ: SYRS) recently:

  • 3/22/2019 – Syros Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 3/8/2019 – Syros Pharmaceuticals had its “mkt outperform” rating reaffirmed by analysts at JMP Securities. They now have a $18.00 price target on the stock.
  • 3/8/2019 – Syros Pharmaceuticals had its “hold” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock. They wrote, “Our price target of $10/share ($4.0 from tamibarotene + $3.4 from platform + $2.6 in cash) is based on a discounted cash flow analysis (2019-2027) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development-stage oncology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing.””
  • 3/8/2019 – Syros Pharmaceuticals was given a new $14.00 price target on by analysts at Roth Capital. They now have a “buy” rating on the stock.
  • 3/7/2019 – Syros Pharmaceuticals was given a new $13.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 2/14/2019 – Syros Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $13.00 price target on the stock.

Syros Pharmaceuticals stock traded up $0.43 during mid-day trading on Friday, reaching $9.14. The company’s stock had a trading volume of 72,180 shares, compared to its average volume of 138,469. The company has a market cap of $285.40 million, a P/E ratio of -4.79 and a beta of 1.22. Syros Pharmaceuticals Inc has a 12 month low of $5.17 and a 12 month high of $13.86.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, March 7th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.05). The business had revenue of $0.89 million during the quarter, compared to the consensus estimate of $0.40 million. Syros Pharmaceuticals had a negative net margin of 3,038.00% and a negative return on equity of 64.43%. As a group, analysts predict that Syros Pharmaceuticals Inc will post -2.1 earnings per share for the current fiscal year.

In related news, major shareholder Venture Fund Vii L.P. Arch sold 167,503 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $7.83, for a total value of $1,311,548.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 27.80% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp grew its position in shares of Syros Pharmaceuticals by 0.7% in the 4th quarter. Northern Trust Corp now owns 306,167 shares of the company’s stock valued at $1,705,000 after acquiring an additional 2,179 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Syros Pharmaceuticals by 3.3% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,561 shares of the company’s stock valued at $683,000 after acquiring an additional 3,900 shares during the period. Bank of New York Mellon Corp grew its position in shares of Syros Pharmaceuticals by 8.9% in the 4th quarter. Bank of New York Mellon Corp now owns 84,537 shares of the company’s stock valued at $470,000 after acquiring an additional 6,883 shares during the period. MetLife Investment Advisors LLC grew its position in shares of Syros Pharmaceuticals by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 20,338 shares of the company’s stock valued at $242,000 after acquiring an additional 7,230 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Syros Pharmaceuticals by 2.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 369,959 shares of the company’s stock valued at $4,406,000 after acquiring an additional 8,286 shares during the period. 67.87% of the stock is owned by institutional investors.

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Featured Article: Trading Ex-Dividend

Receive News & Ratings for Syros Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.